Education
About Us
Working with TipRanks
Follow Us
Indivior PLC (INDV)
NASDAQ:INDV
INDV Stock Chart & Stats
$33.48
--
Market closed
$33.48
--
Day’s Range― - ―
52-Week Range$7.62 - $33.64
Previous CloseN/A
VolumeN/A
Average Volume (3M)2.18M
Market Cap
$4.18B
Enterprise Value$3.02B
Total Cash (Recent Filing)$445.00M
Total Debt (Recent Filing)$356.00M
Price to Earnings (P/E)33.3
Beta0.64
Next Earnings
Feb 12, 2026EPS Estimate
0.68Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.72
Shares Outstanding124,853,900
10 Day Avg. Volume1,750,690
30 Day Avg. Volume2,184,172
Financial Highlights & Ratios
PEG Ratio239.55
Price to Book (P/B)-4.71
Price to Sales (P/S)1.38
P/FCF Ratio234.39
Enterprise Value/Market Cap0.72
Enterprise Value/Revenue2.56
Enterprise Value/Gross Profit3.09
Enterprise Value/Ebitda9.59
Forecast
1Y Price Target
$38.67Price Target Upside15.50% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)2.26
Revenue Forecast (FY)$1.17B
Bulls Say, Bears Say
Bulls Say
EarningsINDV reported a strong third quarter that exceeded expectations across all key metrics and validated the positive call on the stock.
Market PositionINDV has a unique position to expand the penetration of long-acting injectables in the treatment of opioid use disorder.
Price TargetThe revised price target is raised to $35 from $28, driven by higher Sublocade forecasts and deeper-than-expected cost reductions.
Bears Say
Indivior News
INDV FAQ
What was Indivior PLC’s price range in the past 12 months?
Indivior PLC lowest stock price was $7.62 and its highest was $33.64 in the past 12 months.
What is Indivior PLC’s market cap?
Indivior PLC’s market cap is $4.18B.
When is Indivior PLC’s upcoming earnings report date?
Indivior PLC’s upcoming earnings report date is Feb 12, 2026 which is in 74 days.
How were Indivior PLC’s earnings last quarter?
Indivior PLC released its earnings results on Oct 30, 2025. The company reported $0.72 earnings per share for the quarter, beating the consensus estimate of $0.412 by $0.308.
Is Indivior PLC overvalued?
According to Wall Street analysts Indivior PLC’s price is currently Undervalued.
Does Indivior PLC pay dividends?
Indivior PLC does not currently pay dividends.
What is Indivior PLC’s EPS estimate?
Indivior PLC’s EPS estimate is 0.68.
How many shares outstanding does Indivior PLC have?
Indivior PLC has 124,853,900 shares outstanding.
What happened to Indivior PLC’s price movement after its last earnings report?
Indivior PLC reported an EPS of $0.72 in its last earnings report, beating expectations of $0.412. Following the earnings report the stock price went up 15.412%.
Which hedge fund is a major shareholder of Indivior PLC?
Currently, no hedge funds are holding shares in INDV
Indivior Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$38.67 (15.50% Upside)
$38.67 (15.50% Upside)
Blogger Sentiment
Bullish
INDV Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 2.0M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.1%
Last 30 Days ▲ 8.0%
Last 30 Days ▲ 8.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
199.46%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-3.28%
Trailing 12-Months
Company Description
Indivior PLC
Indivior PLC is a global pharmaceutical company focused on the treatment of substance use disorders and mental health conditions. Established as a spinoff from Reckitt Benckiser in 2014, Indivior specializes in developing innovative medications that address opioid dependence, with its flagship product being Suboxone, a combination of buprenorphine and naloxone. The company operates primarily in the healthcare sector, working to improve patient outcomes through its proprietary therapies and support programs for addiction treatment.
INDV Company Deck
INDV Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a generally optimistic outlook with strong performance and growth in SUBLOCADE, raised financial guidance, and significant cost-saving initiatives. However, organizational restructuring costs and challenges in expanding the LAI market were noted as concerns.View all INDV earnings summariesINDV Stock 12 Month Forecast
Average Price Target
$38.67
▲(15.50% Upside)
Technical Analysis
Pacira Pharmaceuticals
―
Supernus Pharmaceuticals
―
ANI Pharmaceuticals
―
Amphastar Pharmaceuticals
―
Evotec AG
―
Ownership Overview
Currently, No data available
---